Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial Meeting Abstract
| Authors: | Bar, N.; Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L. O.; Isufi, I.; Harrison, S. J.; Shah, U. A.; De Champlain, A.; Gries, K. S.; Chen, D.; Li, Q.; Yeh, T. M.; Slaughter, A.; Lonardi, C.; Benachour, N.; Ghosh, A.; Deraedt, W.; Vogel, M.; Lendvai, N.; Patel, N.; Costa Filho, O.; Florendo, E.; Karlin, L.; Weisel, K. C. |
| Abstract Title: | Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 2003 |
| Language: | English |
| ACCESSION: | WOS:001412856700026 |
| DOI: | 10.1182/blood-2024-209232 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
